Cargando…

The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients

Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Egeland, Nina G., Lunde, Siri, Jonsdottir, Kristin, Lende, Tone H., Cronin-Fenton, Deirdre, Gilje, Bjørnar, Janssen, Emiel A. M., Søiland, Håvard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632748/
https://www.ncbi.nlm.nih.gov/pubmed/26473850
http://dx.doi.org/10.3390/ijms161024243
_version_ 1782399087348285440
author Egeland, Nina G.
Lunde, Siri
Jonsdottir, Kristin
Lende, Tone H.
Cronin-Fenton, Deirdre
Gilje, Bjørnar
Janssen, Emiel A. M.
Søiland, Håvard
author_facet Egeland, Nina G.
Lunde, Siri
Jonsdottir, Kristin
Lende, Tone H.
Cronin-Fenton, Deirdre
Gilje, Bjørnar
Janssen, Emiel A. M.
Søiland, Håvard
author_sort Egeland, Nina G.
collection PubMed
description Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers that may be used to monitor predictors of treatment response. MicroRNAs are promising biomarkers that may fill the gap between preclinical knowledge and clinical observations regarding endocrine resistance. MicroRNAs regulate gene expression by posttranscriptional repression or degradation of mRNA, most often leading to gene silencing. MicroRNAs have been identified directly in the primary tumor, but also in the circulation of breast cancer patients. The few available studies investigating microRNA in patients suggest that seven microRNAs (miR-10a, miR-26, miR-30c, miR-126a, miR-210, miR-342 and miR-519a) play a role in tamoxifen resistance. Ingenuity Pathway Analysis (IPA) reveals that these seven microRNAs interact more readily with estrogen receptor (ER)-independent pathways than ER-related signaling pathways. Some of these pathways are targetable (e.g., PIK3CA), suggesting that microRNAs as biomarkers of endocrine resistance may have clinical value. Validation of the role of these candidate microRNAs in large prospective studies is warranted.
format Online
Article
Text
id pubmed-4632748
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-46327482015-11-23 The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients Egeland, Nina G. Lunde, Siri Jonsdottir, Kristin Lende, Tone H. Cronin-Fenton, Deirdre Gilje, Bjørnar Janssen, Emiel A. M. Søiland, Håvard Int J Mol Sci Review Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers that may be used to monitor predictors of treatment response. MicroRNAs are promising biomarkers that may fill the gap between preclinical knowledge and clinical observations regarding endocrine resistance. MicroRNAs regulate gene expression by posttranscriptional repression or degradation of mRNA, most often leading to gene silencing. MicroRNAs have been identified directly in the primary tumor, but also in the circulation of breast cancer patients. The few available studies investigating microRNA in patients suggest that seven microRNAs (miR-10a, miR-26, miR-30c, miR-126a, miR-210, miR-342 and miR-519a) play a role in tamoxifen resistance. Ingenuity Pathway Analysis (IPA) reveals that these seven microRNAs interact more readily with estrogen receptor (ER)-independent pathways than ER-related signaling pathways. Some of these pathways are targetable (e.g., PIK3CA), suggesting that microRNAs as biomarkers of endocrine resistance may have clinical value. Validation of the role of these candidate microRNAs in large prospective studies is warranted. MDPI 2015-10-14 /pmc/articles/PMC4632748/ /pubmed/26473850 http://dx.doi.org/10.3390/ijms161024243 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Egeland, Nina G.
Lunde, Siri
Jonsdottir, Kristin
Lende, Tone H.
Cronin-Fenton, Deirdre
Gilje, Bjørnar
Janssen, Emiel A. M.
Søiland, Håvard
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
title The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
title_full The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
title_fullStr The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
title_full_unstemmed The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
title_short The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
title_sort role of micrornas as predictors of response to tamoxifen treatment in breast cancer patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632748/
https://www.ncbi.nlm.nih.gov/pubmed/26473850
http://dx.doi.org/10.3390/ijms161024243
work_keys_str_mv AT egelandninag theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT lundesiri theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT jonsdottirkristin theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT lendetoneh theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT croninfentondeirdre theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT giljebjørnar theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT janssenemielam theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT søilandhavard theroleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT egelandninag roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT lundesiri roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT jonsdottirkristin roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT lendetoneh roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT croninfentondeirdre roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT giljebjørnar roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT janssenemielam roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients
AT søilandhavard roleofmicrornasaspredictorsofresponsetotamoxifentreatmentinbreastcancerpatients